<![CDATA[Seattle Genetics, Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=23346>Fri, 24 Apr 2026 19:04:25 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma]]>https://www.newswire.co.kr/newsRead.php?no=857411Fri, 06 Oct 2017 15:25:00 +0900<![CDATA[Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma]]>https://www.newswire.co.kr/newsRead.php?no=851249Thu, 08 Jun 2017 18:55:00 +0900<![CDATA[Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma]]>https://www.newswire.co.kr/newsRead.php?no=839345Wed, 09 Nov 2016 11:20:00 +0900<![CDATA[Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma]]>https://www.newswire.co.kr/newsRead.php?no=768220Tue, 30 Sep 2014 15:15:00 +0900<![CDATA[시애틀 제네틱스와 다케다, 애드세트리스(ADCETRIS®) 임상 3상 시험 AETHERA에서 긍정적 결과 도출…이식 후 호지킨 림프종 환자의 공고요법 시험]]>https://www.newswire.co.kr/newsRead.php?no=768221Tue, 30 Sep 2014 15:15:00 +0900